Treatment of chronic proliferative cholangitis with c-myc shRNA.

World Journal of Gastroenterology : WJG
Fu-Yu LiSheng He

Abstract

To investigate the feasibility and effectiveness of c-myc shRNA in inhibiting the hyperplastic behavior and lithogenic potentiality of chronic proliferative cholangitis (CPC), in order to prevent stone recurrence and biliary restenosis. An animal model of CPC was established by giving intralumenally 0.5 mL of c-myc shRNA. Then, the effects of c-myc shRNA on hyperplastic behavior and lithogenic potentiality of CPC were evaluated by histological observation, immunohistochemistry, real-time PCR and Western blotting for c-myc, proliferating cell nuclear antigen (PCNA), procollagen III, mucin 5AC, enzymatic histochemistry for beta-glucuronidase, and biochemistry for hydroxyproline in the diseased bile duct. Treatment with c-myc shRNA efficiently suppressed the hyperplasia of biliary epithelium, submucosal gland, and collagen fiber by inhibiting mRNA and protein expression of c-myc. More importantly, it decreased the lithogenic potentiality of CPC by inhibiting the expression of mucin 5AC and the secretion of endogenous beta-glucuronidase. Further investigation indicated that c-myc shRNA-3 had a better inhibitory effect on CPC. Treatment with c-myc shRNA-3 can control CPC and reduce the lithogenic potentiality of CPC.

References

Jan 1, 1992·Journal of Gastroenterology and Hepatology·T YamasakiM Endo
Nov 1, 1990·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·T Terada, Y Nakanuma
Oct 1, 1988·Human Pathology·Y NakanumaT Terada
Oct 1, 1986·World Journal of Surgery·Y MatsumotoK Sugahara
Jun 1, 1968·The American Journal of Digestive Diseases·B Ballantyne, W G Wood
Mar 15, 1981·Analytical Biochemistry·I S JamallS S Que Hee
Oct 1, 1995·Circulation·M R Bennett, S M Schwartz
Feb 1, 1995·Circulation Research·E R EdelmanR D Rosenberg
Feb 1, 1995·Archives of Surgery·K ChijiiwaM Tanaka
Jan 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·S BiroS E Epstein
Jan 1, 1996·Current Topics in Microbiology and Immunology·B HoffmanH Q Nguyen
Aug 16, 2000·Vascular Medicine·A Ehsan, M J Mann
Aug 15, 2003·World Journal of Gastroenterology : WJG·Hai-Ming YangMin-Fei Zhou
Sep 25, 2003·Journal of Hepato-biliary-pancreatic Surgery·Seon-Mee ParkYong-Hyun Park
Apr 17, 2004·Journal of Clinical Gastroenterology·Jin-Hyeok HwangJi Bong Jeong
Jan 6, 2005·World Journal of Gastroenterology : WJG·Zhi-Min GengXiao-Gong Liu
Feb 21, 2006·World Journal of Gastroenterology : WJG·Bong-Wan KimMyung-Wook Kim
May 18, 2006·Journal of Gastroenterology and Hepatology·Fu-Yu LiNan-Sheng Cheng
May 24, 2006·World Journal of Gastroenterology : WJG·Marilee-L FreitasAndrew-J Duffy
Jul 11, 2006·World Journal of Gastroenterology : WJG·Shao-Qiang LiDong-Ming Li
Aug 19, 2007·World Journal of Gastroenterology : WJG·Giovanni D De PalmaGiovanni Persico
May 29, 2008·World Journal of Gastroenterology : WJG·Andreas WeberChristian Prinz
Aug 30, 2008·World Journal of Gastroenterology : WJG·Zhi-Min GengLin Wang

❮ Previous
Next ❯

Citations

Sep 23, 2010·Virology Journal·Katja Sliva, Barbara S Schnierle
Dec 14, 2011·Biochemical and Biophysical Research Communications·Yongchao LiuJie Fan
May 10, 2020·Current Gastroenterology Reports·Eric LorioHari Sayana
May 23, 2019·International Journal of Molecular Medicine·San-Hu LiuJie Zhou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Barrett Esophagus

Barrett’s esophagus if a serious complication of gastroesophageal reflux disease during which the normal esophageal lining changes to tissue that resembles intestinal lining. Here is the latest research.